NCT04416906

A Test and Treat Strategy in New HIV Diagnosis.

A Test and Treat Strategy in Barcelona: A Prospective Study in New HIV Diagnosis.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Judit Pich Martínez · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, single arm, single-centre prospective study to evaluate the feasibility, efficacy and safety of a once daily fixed dose combination regimen, Biktarvy, as a rapid treatment strategy in newly HIV diagnosed patients that come for the first time to the Hospital Clínic HIV Unit Patients with confirmed HIV-1 diagnosis who wish to start ARV treatment immediately will receive bictegravir 50 mg + emtricitabine 200 mg + tenofovir alafenamide 25 mg within the first week since the HIV-1 confirmation during 48 weeks.

Conditions

• HIV-1-infection

Interventions

Type	Name	Description
DRUG	Biktarvy	Once daily fixed dose combination regimen of Biktarvy will be evaluated as a rapid treatment strategy in newly HIV diagnosed patients HIV diagnosed patients that come for the first time to the Hospital Clínic HIV Unit

Timeline

• Start date: 2020-10-05
• Primary completion: 2023-05-11
• Completion: 2023-05-11
• First posted: 2020-06-04
• Last updated: 2023-09-18

Locations

1 site across 1 country: Spain